How is Prostate cancer diagnosed?

['Engkalingai iyaé bagiyangngé']

Pékkugi kanker prostat riaddiagnosis?

Kanker prostat riaddiagnosis lalo kombinasi tes nenniya prosedur, iya nulle mattamani:

1. Digital Rectal Exam (DRE): Seddie doktere naputtama jari iya paké sarung tangan, sibawa naleppa'i minnya' ri laleng rektum untu' narasa' prostat untu' engka abnormalitas.

2. Uji Prostate-Specific Antigen (PSA): Iyyae iyanaritu seddi uji dara iya naukkuru tingka' PSA, seddi protein iya riwasseleki pole kelenjar prostat.

Tingka PSA iya matanre nulle mappaita engka kanker prostat.

3. Transrectal Ultrasound (TRUS): Seddie probe baiccu ritaroi ri laleng rektum untu' makkebbu gambara prostat mappake bombang suara.

Iyyae nulle natulung untu' naidentifikasi sininna abnormalitas ri kelenjar prostat.

4. Biopsi: Seddi sampel baiccu jaringan prostat ripassu nenniya riperiksa ri yawa mikroskop untu' engka sel kanker.

Iyyae iyyanaritu seddi-seddinna cara mattentu untu' nasappai kanker prostat.

5. Magnetic Resonance Imaging (MRI): MRI scan prostat wedding bantui natentuang sininna abnormalitas nenniya napimping prosedur biopsi.

6. Uji Genomik: Siare dokter nulle mappake uji genomik untu' bantu pattentui agresivitas kanker nenniya pimping apettung pabbura.

7. Bone Scan: Bone scan nulle ripigau untu' paressai narekko kanker e mallebbang lao ri bukunna.

8. Computed Tomography (CT) Scan: CT scan nulle ripakkeguna untu' paressai narekko kanker e mallebbang lao ri organ iyarega jaringan laing e.

Parellu riisseng majeppu dee yamaneng urane sibawa tingka' PSA iyya matanre iyarega wassele DRE iyya de'e na biasa punnai kanker prostat, nenniyya dee yamaneng kanker prostat nassabari tingka' PSA iyya matanre.

Rimakkuwannanaro, parellu biopsi untu' napattentu diagnosis.

Rilainnaero, apettung untu' nalai biopsi ripigau purana naitai wassele'na tes e nenniya faktor resiko nenniya pappile'na individu e.

['Rilaleng']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.

Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.

Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.

Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.

McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.

An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.

[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.

Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.

['Atassalang: medis']

["Iyyae situs web e ripassedia untu' akkatta-akkatta pendidikan nenniya informasi bawang na de'na mabbere saran medis iyarega layanan profesional."]

["Kareba iya riwerengnge de'na nawedding ripakkeguna untu' napannessai yarega napajjappai passaleng yarega lasa kesehatang, nenniya tau iya sappaeng pangajana medis pribadi harusu'i nasappai sibawa dottoro' iya berlisensi."]

["Rilaleng iyyae, jaringang saraf iya makkewassele bali lao ri pakkutanae, de'na coco narekko engka assisompungenna sibawa angke. contona, egana tau iya riruntue sibawa lasa mattentu."]

["Tuli sappai pangajana doktere'mu iyarega pajjama kesehatang laingnge iyya engkae kualifikasi'e ri tujunna keadaang medis'e. Aja' naengka muwallupai pangajana doktere' iyarega matengnge ri laleng sappa'na nasaba engka aga pura mubaca ri situs web'e. Narekko muwasengngi engka passaleng medis iya parellu'e ripassappa, mobbii 911 iyarega lao ri ruang darurat kaminang macawe'e masitta'. De gaga assisompungeng doktere-pasien iyya ripancaji pole situs web'e iyarega akkegunanna. BioMedLib iyarega pajjamana, iyarega muwi niga pattarima lao ri situs web'e, de nawerengngi aga-aga, manessa iyarega tersirat, ri tujunna kareba iyya riyabbere'e iyarega akkegunanna."]

['Disclaimer: hak cipta']

["Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) mabbere daya tarik lao ri punnana hak cipta iya mateppe'e majeppuu agaaga iya engkae ri Internet naruntu'i hakna ri yawa hukung hak cipta AS. "]

["Narekko mateppe'ko sibawa makessing majeppuu agaaga lise'na iyarega agaaga iya engkae ri laleng situs web iyarega jasae naruntu'i hak cipta'mu, iko (iyarega agenna) wedding kiringki pappaseng iyya naeloriwi lise' iyarega agaaga ripassu, iyarega akses lao ri iyyae ritongkoi."]

['Appallebbangenna parellui rikiring secara maruki sibawa email (itai "Kontak" bagiang untu\' alamat email). ']

["DMCA parellu i nawereng pappaseng mu ri palanggarang hak cipta nawereng i pappaseng iyyae: (1) pappaseng pole ri jama-jamang hak cipta iyyae mancaji pakkitanna palanggarang iya nawereng i; (2) pappaseng pole ri konten iya nawereng i nenniya pappaseng iya genne'e untu' nawereng i onrong konten e; (3) pappaseng assisumpungemmu, matame' alamat, nomoro' telepon, nenniya alamat emailmu; (4) pappaseng pole ri iko makkedae iko mateppe'i majeppu konten iya engkae rilalenna pappaseng iyya mu nawereng i de'na ripalaloi pole ri punnana hak cipta, iyarega agen na, iyarega pole ri hukum e; "]

["(5) seddi pappaseng pole ri iko, ritanrai ri yawa pahukkungeng sabbi bellé, makkeda kareba ri laleng pappasengnge coco'i sibawa iko mappunnaiwi otoritas untu' napake hak cipta iya rituntut pura rikalang;"]

["nenniya (6) tanrang lima fisik iyarega elektronik pole punnana hak cipta iyarega tau iya ripalalo e untu' majjama ri laleng asenna punnana hak cipta e. "]

["Narekko de'na ripasseddi sininna kareba riase'e nulle nassabari ritunda'na attarimai reklamo'mu."]

['Kontak iya']

['Tulung kiringki email sibawa pakkutana/pahang.']

How is prostate cancer diagnosed?

Prostate cancer is diagnosed through a combination of tests and procedures, which may include:

1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.

2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.

Elevated PSA levels may indicate the presence of prostate cancer.

3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.

This can help identify any abnormalities in the prostate gland.

4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.

This is the only definitive way to diagnose prostate cancer.

5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.

6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.

7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.

8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.

It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.

Therefore, a biopsy is necessary to confirm the diagnosis.

Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.